

**ASX Code: GSS**  
22 March 2019

## Change in Director's Interest Notice

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) advises that Non-Executive Director, Dr Anthony Radford, has sold 107,000 shares in GSS to fund expected tax obligations triggered from the release of shares held in escrow.

Post the sale, Dr Radford still retains 240,000 shares.

The sale was conducted in accordance with the Company's Share Trading Policy.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**  
**Chief Executive Officer**  
[john@geneticsignatures.com](mailto:john@geneticsignatures.com)

**Peter Manley**  
**Chief Financial Officer**  
[peter.manley@geneticsignatures.com](mailto:peter.manley@geneticsignatures.com)

T: +61 (0)2 9870 7580

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**<sup>™</sup>. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*<sup>™</sup> brand. Genetic Signatures' proprietary MDx **3base**<sup>™</sup> platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

## Appendix 3Y

### Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	GENETIC SIGNATURES LIMITED
<b>ABN</b>	30 095 913 205

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Anthony (Tony) Radford
<b>Date of last notice</b>	24 October 2016

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.		Koona Nominees Pty Ltd (Trustee of the self managed super fund of which Tony Radford is a director)
<b>Date of change</b>	-	15 & 18 March 2019
<b>No. of securities held prior to change</b>	240,000	107,000
<b>Class</b>	170,00 FPO shares 70,000 GSS Employee Share Plan (ESP) shares	FPO shares
<b>Number acquired</b>	Nil	Nil
<b>Number disposed</b>	Nil	107,000
<b>Value/Consideration</b> <input type="checkbox"/> Note: If consideration is non-cash, provide details and estimated valuation <input type="checkbox"/>	-	\$124,053.30

+ See chapter 19 for defined terms.

<b>No. of securities held after change</b>	240,000	Nil
<b>Nature of change</b> <input type="checkbox"/> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	N/a	On market trade

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/a
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <input type="checkbox"/> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a

<sup>+</sup> See chapter 19 for defined terms.